Novavax, Inc.
NVAX
$8.05
-$0.09-1.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -61.64% | -52.48% | 64.69% | 20.27% | 9.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.64% | -52.48% | 64.69% | 20.27% | 9.22% |
| Cost of Revenue | -12.09% | -20.21% | -31.95% | -35.46% | -37.58% |
| Gross Profit | -101.78% | -77.01% | 793.45% | 233.49% | 178.13% |
| SG&A Expenses | -52.66% | -56.33% | -51.77% | -54.90% | -49.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.16% | -32.81% | -38.71% | -44.88% | -44.06% |
| Operating Income | -132.56% | -91.20% | 342.85% | 243.72% | 228.18% |
| Income Before Tax | -156.87% | -117.64% | 350.36% | 225.36% | 249.33% |
| Income Tax Expenses | -71.80% | -83.20% | -82.86% | 74.47% | 56.89% |
| Earnings from Continuing Operations | -158.59% | -118.35% | 334.83% | 219.97% | 243.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.59% | -118.35% | 334.83% | 219.97% | 243.65% |
| EBIT | -132.56% | -91.20% | 342.85% | 243.72% | 228.18% |
| EBITDA | -124.90% | -87.27% | 422.10% | 285.75% | 269.48% |
| EPS Basic | -158.19% | -117.68% | 323.82% | 198.38% | 198.02% |
| Normalized Basic EPS | -124.36% | -86.46% | 366.55% | 232.43% | 194.50% |
| EPS Diluted | -166.74% | -121.94% | 281.67% | 179.33% | 182.58% |
| Normalized Diluted EPS | -128.74% | -86.69% | 320.85% | 208.54% | 176.99% |
| Average Basic Shares Outstanding | 1.46% | 3.25% | 6.47% | 12.87% | 24.83% |
| Average Diluted Shares Outstanding | -2.92% | 0.64% | 8.99% | 14.92% | 26.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |